Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026
Go back to Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026| (NASDAQ: PSNL) | Delayed: 10.17 -0.37 (3.51%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $10.54 | 52 Week High | $ | |||
| Open | $10.49 | 52 Week Low | $ | |||
| Day High | $10.86 | P/E | N/A | |||
| Day Low | $9.65 | EPS | $ | |||
| Volume | 2,506,301 | |||||
